PPARD

Gene

peroxisome proliferator activated receptor delta

HGNCHGNC:9235 EnsemblENSG00000112033 NCBI Gene5467

Locus: gene with protein productLocation: 6p21.31

Encodes

via encodes

The protein product this gene encodes, reached through the canonical GENE→PROTEIN (encodes) relation. Its biology, drugs, indications, trials and therapeutic evidence live on the protein's own page.

Peroxisome proliferator-activated receptor deltaQ03181

Protein · therapeutic target

Clinically validated target · 3 approved medicines against this target

Member of “Peroxisome Proliferator-Activated Receptors” · 4 related family papers (context, not papers about this gene)

Explore protein biology & therapeutics

Also known as

Symbols and names change; identity (the HGNC ID) does not. Previous and alternative forms are kept distinct.

Also known asNUC1 · NUCII · FAAR · NR1C2 · PPARB

View full nomenclature history (8)

Alias symbolsNUC1, NUCII, FAAR, NR1C2, PPARB

Previous namesperoxisome proliferative activated receptor, delta, peroxisome proliferator-activated receptor delta

Alias namesperoxisome proliferator activated receptor beta

Associated diseases

via associated_with

Diseases linked to this gene through the canonical GENE→DISEASE (associated_with) relation, drawn from Open Targets' top-ranked associations by overall score — not the full association set. Disease-level detail lives on each disease's own page.

Biliary liver cirrhosis

Neurodegenerative Diseases

Primary biliary cholangitis

Diabetes Mellitus, Type 2

Hyperlipidemias

Cardiovascular Diseases

Non-alcoholic Fatty Liver Disease

Drawn from Open Targets’ top 10 associations by overall score for this gene — the subset resolved to a canonical disease. Lower-ranked associations, and diseases not yet canonicalised, are not shown.

Gene family

HGNC gene-group membership.

Peroxisome proliferator activated receptors

Provenance

HGNCCanonical human gene identity from HGNC (release 2026-07-07), updated 2023-01-20.

Open TargetsGene–disease associations from the Open Targets Platform.